Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing
Brief Summary: The purpose of this study is to compare the efficacy and safety profile of a new oral vitamin B12 formulation (Eligen® B12) with intramuscular B12 in restoring normal B12 (cobalamin) concentrations in subjects with low cobalamin levels (\<350 pg/mL).


Options:
A: Inclusion Criteria:

* Undergone total gastrectomy for gastric cancer
* Regular follow up is possible
* Serum vit,. B12 \< 200pg/ml

Exclusion Criteria:

* Has diseases other than stomach cancer
* Patients with other kinds of oral supplementation (multi-vitamins)
B: Inclusion Criteria:

* ≥ 65 aged patients with Cobalamin Deficiency.
* Patients give inform consent.

Exclusion Criteria:

* Treatment with B12 (1 last year)
* Neurologic or psychiatric pathologies
* Folic acid \< 2.3ng/ml ...
C: Inclusion Criteria:

* Vitamin B12 deficiency defined as serum cobalamin below 350 pg/mL
* Age 60 or older; or age 18 or older with gastrointestinal abnormalities including but not limited to gastrointestinal surgery (e.g. gastrectomy, gastric bypass), ileal resection, gastric atrophy, Celiac disease, Crohn's disease, or prolonged use (\>3 months) of proton pump inhibitor drugs, or on a restricted diet (such as vegetarian or vegan).
* General good health, as indicated by lack of significant findings in medical history, physical examination, clinical laboratory tests (chemistry, hematology and urinalysis), vital signs, ECG and normal kidney function as determined by estimated creatinine clearance computed with the Cockcroft and Gault formula

Exclusion Criteria:

* Current treatment from a health care provider to treat vitamin B12 deficiency and/or symptoms;
* Daily use of neutralizing antacids (e.g. Maalox®)
* Inability to ingest oral medication
* Clinically significant laboratory value at screening
* Hypersensitivity or allergic reaction to vitamin B12
* Participation in a clinical research study involving a new chemical entity within 30 days of the first study dose
* Folate levels below the reference range provided by the clinical laboratory.
* Renal insufficiency
* Vitamin B6 deficiency
D: Inclusion Criteria:

* Patients of both sexes (women after menopause, women of child-bearing age after sterilization or if practicing reliable contraception)
* Type 2 DM requiring insulin therapy after failure of maximal oral antidiabetic treatment (glycosylated Hb \> 7.5%) and need for exogenous insulin. (No concomitant use of oral antidiabetic agents)
* Being ambulatory
* Age: 30 to 80 years
* Proven absence of Islet Antibodies, if QI \< 28 kg/m2
* Insulin therapy 4 times daily (21), or insulin therapy 2 times daily using insulin 'mixtures' (rapidly and slowly acting)
* Standard dietary prescription by the dietician
* Absence of keto-acidosis
* Informed consent

Exclusion Criteria:

* Congestive heart failure, NYHA-classes III or IV
* Cardiac failure and/or myocardial infarction in the last four months before enrolment
* Other severe organic / systemic disease
* Metformin-induced lactic-acidosis
* Intolerance to metformin hydrochloride
* Renal disease or renal dysfunction
* Hypoxic states
* Severe hepatic dysfunction
* Excessive alcohol intake, acute or chronic
* Acute or chronic metabolic acidosis

Answer: C